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Somatic mTOR mutation in clonally expanded T
lymphocytes associated with chronic graft versus
host disease
Daehong Kim 1,2,13, Giljun Park 1,2,13, Jani Huuhtanen 1,2, Sofie Lundgren1,2, Rajiv K. Khajuria1,
Ana M. Hurtado 3, Cecilia Muñoz-Calleja4, Laura Cardeñoso5, Valle Gómez-García de Soria6,
Tzu Hua Chen-Liang 3, Samuli Eldfors 7, Pekka Ellonen7, Sari Hannula7, Matti Kankainen1,2,8,9,
Oscar Bruck 1,2,9, Anna Kreutzman1,2, Urpu Salmenniemi10, Tapio Lönnberg11, Andrés Jerez3,
Maija Itälä-Remes10, Mikko Myllymäki 1,2, Mikko A. I. Keränen1,2,12 & Satu Mustjoki 1,2,9✉
Graft versus host disease (GvHD) is the main complication of allogeneic hematopoietic stem
cell transplantation (HSCT). Here we report studies of a patient with chronic GvHD (cGvHD)
carrying persistent CD4+ T cell clonal expansion harboring somatic mTOR, NFKB2, and TLR2
mutations. In the screening cohort (n= 134), we detect the mTOR P2229R kinase domain
mutation in two additional cGvHD patients, but not in healthy or HSCT patients without
cGvHD. Functional analyses of the mTOR mutation indicate a gain-of-function alteration and
activation of both mTORC1 and mTORC2 signaling pathways, leading to increased cell
proliferation and decreased apoptosis. Single-cell RNA sequencing and real-time impedance
measurements support increased cytotoxicity of mutated CD4+ T cells. High throughput
drug-sensitivity testing suggests that mutations induce resistance to mTOR inhibitors, but
increase sensitivity for HSP90 inhibitors. Our findings imply that somatic mutations may
contribute to aberrant T cell proliferations and persistent immune activation in cGvHD,
thereby paving the way for targeted therapies.
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Graft versus host disease (GvHD) is a major source ofmorbidity and mortality after allogeneic hematopoieticstem cell transplantation (allo-HSCT)1. Chronic GvHD
(cGvHD) occurs after day 100 post-transplantation and develops
in 30–70% of allo-HSCT recipients2. The 5-year mortality rate is
30–50% and can be attributable to immune dysregulation and
infections3. Affected patients frequently need immunosuppressive
treatment for years or even for a lifetime.
The pathophysiology of cGvHD is multifactorial. Engrafted
donor CD4+ T cells contribute to tissue injury, inflammation,
and late aberrant tissue repair and fibrosis, making them candi-
date therapy targets in cGvHD4. In many immune system
mediated disorders, such as cGvHD, the immune homeostasis is
disturbed, and the enormous variability of T cell receptor (TCR)
repertoire is diminished. In some patients, clonal expansions
comprising up to 20–40% of all T cells can exist5–7. While
somatic mutations have been identified in clonally expanded
T cells in human diseases, such as in large granular lymphocyte
(LGL) leukemia8–10, aplastic anemia (AA)11, and rheumatoid
arthritis12, the prevalence and impact of this phenomenon has
not been investigated in patients with cGvHD.
Here, we hypothesize that in cGvHD activated T cells may
acquire somatic mutations due to constant immune-system
activation and proliferation. Such mutations might lead to func-
tional and survival advantage, resulting in clonal expansion and
further activation of the immune response. To explore this the-
ory, we purify CD4+ and CD8+ lymphocytes from an index
patient suffering from persistent cGvHD despite long-term
immunosuppressive therapies and sequence them with a cus-
tom deep-sequencing panel consisting of immunity and
inflammation-related genes. We study the discovered mutations
in a validation cohort of 134 cGvHD patients. Subsequently, we
evaluate the functional consequences of the discovered mutations
in vitro. Finally, we verify these observations in patient cells using
drug sensitivity screening and unbiased transcriptome-wide sin-
gle-cell RNA-sequencing (scRNA-seq) paired with TCR alpha
and beta sequencing (TCRαβ-seq) analysis and functional cyto-
toxicity assays.
Results
Clinical characteristics of the index cGvHD patient. The index
patient was a 56-year-old male, who was diagnosed with chronic
phase chronic myeloid leukemia in 1999. The patient received an
allogeneic bone marrow transplantation in 2000. Since the
beginning of 2001, the patient suffered from cGvHD affecting his
liver, eyes, nails, and skin. The immunosuppression was con-
tinuously adjusted according to the clinical presentation of the
cGvHD. The clinical status and treatment history are described in
detail in Supplementary Fig. 1 and Supplementary results.
Immunophenotype and TCR repertoire of T cells. During the
first sampling in 2013, the patient was on mycophenolate mofetil
therapy. TCR repertoire was initially analyzed with a flow
cytometry-based assay using a panel of TCR Vβ-specific anti-
bodies with the sample obtained in 2015. A large clonal Vβ20+
expansion was noted among CD4+ T cells (Fig. 1a, b). The
Vβ20+ clone constituted 52.9% of total CD4+ T cells, and it
increased over time (Fig. 1a, c). Smaller clonal expansions were
detected in total CD8+ T cells, but not the Vβ20+ expansion
(Fig. 1a, Supplementary Fig. 2). To assess the repertoire in more
detail, FACS-sorted CD4+ Vβ20+, CD4+ Vβ20−, and CD8+
T cells were further analyzed by a TCRβ deep-sequencing assay12,
which confirmed the TCRBV30-01 expansion (corresponding to
the Vβ20+ expansion observed by flow cytometry) in the CD4
+Vβ20+ fraction (66.2% of sorted cells) (Fig. 1d). TCRβ
sequencing of CD8+ T cells revealed two clones, TCRBV07-09
(16.1%) and TCRBV28-01 (17.9%) (Fig. 1d).
During an exacerbation of sclerodermatous skin lesions in
2015, 59% of peripheral blood leukocytes were T cells, 5% B cells,
and 35% NK cells (Supplementary Fig. 2a). CD3+ T cells were
composed of CD4+ (59.3%), CD4+CD8+ (11.3%), and CD8+
T cells (12.6%) (Supplementary Fig. 2b). An increased number of
CD4+ effector memory (EM, 75.0%) and terminally differentiated
effector memory (TEMRA) cells (17.4%) was found together with
a decreased number of CD4+ central memory (CM) cells (6.2%)
when compared with the sibling HSCT donor’s CD4+ T cell pool
(59.6% EM, 5.0% TEMRA, and 19.9% CM cells) (Fig. 1e). In the
CD8+ T cell pool, increased amount of TEMRA cells was noted
(79.9% of CD8+ T cells). The proportion of cells positive for
cytotoxic enzyme granzyme B (GrB) was notably high both
among CD4+ and CD8+ T cells (46% and 87%, respectively,
Fig. 1f).
Somatic mutations in the expanded CD4+ T cell population.
To screen for somatic mutations, a customized immunity and
inflammation-related gene sequencing panel (immunogene
panel)12,13 was applied to immunomagnetic bead-separated blood
CD4+ and CD8+ T cells that were obtained from the index
patient in 2013. The median target gene coverage for the panel
was 152 in CD4+ and 160 for CD8+ T cells. In total, 14 candidate
putative somatic mutations were discovered within the CD4+
T cells (Table 1), and one in CD8+ T cells (Supplementary
Table 1a). Based on the known biological significance, three of the
mutations (mTOR, NFκB2, and TLR2) were considered as puta-
tive driver mutations and potentially important for disease
pathogenesis and were studied further.
The previously undescribed somatic missense mutation in
mTOR (position 11182160, G to C) changes the amino acid
proline 2229 to arginine (Fig. 2a). The variant allele frequency
(VAF) was 13.3% among CD4+ T cells (Table 1). This mutation
in exon 48 is located in the kinase domain which has been
suggested to be important for signal transduction14,15. In addition
to mTOR, two other interesting mutations were identified in the
NFκB2 and TLR2 genes, although the sequencing coverage of
these regions was not optimal (Table 1).
The NFκB2 missense mutation (position 104162075, C to A)
leads to a change of the amino acid proline 882 to glutamine.
TLR2missense mutation (position 154625732, G to T) results in a
change of the amino acid tryptophan 558 to leucine (Fig. 2a). We
also performed exome sequencing of CD4+, CD8+ T cells, and
NK-cells obtained from the index patient in 2015 (Supplementary
Tables 1b–d). Altogether, 17 candidate putative somatic muta-
tions were discovered within the CD4+ T cell population,
including those in the mTOR, TLR2, and NFκB2 genes
(Supplementary Table 1).
Sequencing validation of the somatic mutations. To further
validate the mTOR P2229R, TLR2 W558L, and NFκB2 P882Q
mutations, CD4+ T cells obtained in 2015 underwent standard
capillary sequencing. Only the mTOR mutation was confirmed
(Fig. 2b) due to the low sensitivity of the assay. Therefore, tar-
geted amplicon sequencing with a coverage up to 100,000X and a
sensitivity of 0.5% VAF16 was applied to all available samples
from different time points to establish the dynamics and the
lineage specificity of the discovered mutations. The mTOR
mutation was detected in CD4+ T cells that were obtained in
2013, 2015, 2017, and 2019 with VAFs 17.3%, 19.2%, 20.5%, and
23.4%, respectively (Table 2 and Supplementary Table 1). The
VAF of the mTOR mutation appeared to increase from 2013 to
2019 regardless of the continuous immunosuppressive therapy
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(Fig. 2c). We next verified the mTOR mutation by amplicon
sequencing from the flow-sorted CD3−, CD8+/CD4−, CD4
+Vβ20−, CD4+CD8+ Vβ20−, and monocyte samples. No
mutations or very low VAFs were detected (Supplementary
Fig. 2b; Supplementary Table 2), suggesting that the mutation was
confined to the CD4+ Vβ20+ cell fraction (VAF 44.7% in flow-
sorted cells).
Similarly, the NFκB2 P882Q mutation was confirmed to be
limited to CD4+Vβ20+ T cells (VAFs: 12.5% in CD4+ T cells
and 21.3% in CD4+Vβ20+ cells) (Table 2 and Supplementary
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Tables 1, 2). In contrast, TLR2 W558L mutation was discovered
in both CD4+ (VAFs: 16.5% in CD4+ cells, 35.5% in CD4+Vβ20
+ cells) and CD8+ T cells (VAF 4.7 %) (Supplementary Tables 3,
4). To examine whether the mutations were already present in the
HSCT donor, both CD4+ and CD8+ T cells from the donor were
sequenced by amplicon sequencing, but no mutations were
detected even with very high sequencing coverage (mTOR, TLR2,
and NFkB2 total depths: 705,188, 403,633, and 395,669,
respectively).
In the course of the disease, the cGvHD affected different
organs of the index patient (liver, eyes, and nails), but particularly
the skin. To explore whether lymphocytes harboring the detected
somatic mutations can be found in target organs, we screened
paraffin-embedded biopsy samples by amplicon sequencing. The
mTOR P2229R mutation was identified in a sclerodermatous skin
lesion that was biopsied in 2015 (VAF 0.8% in Fig. 2d; Table 2),
but not in eye or liver biopsies. Immunofluorescence staining
demonstrated CD4+ and CD8+ T cell infiltration in the same
sclerodermatous lesion (Fig. 2e).
Screening for the somatic mutations in cGvHD patient cohort.
To explore whether the mutations identified in the index patient
are recurrent, blood samples from 134 cGvHD patients, 38 allo-
HSCT patients without cGvHD, and 54 healthy controls were
screened by the amplicon sequencing panel. Two additional
cGvHD patients carried the same mTOR missense mutation
yielding in a mTOR P2229R mutation frequency of 2.2% in all
cGvHD patients (3 out of 135, including the index patient). In the
other two patients, mTOR mutation was also detected during
active period of cGvHD. Using serial samples of one patient, the
detection of the mTOR mutation matched the onset of cGvHD,
and after the successful corticosteroid therapy the mTOR muta-
tion was no longer detectable in the follow-up samples (clinical
characteristics described in detail in the Supplementary results).
In healthy controls or allo-HSCT patients without cGvHD, no
mTOR mutations were detected. Furthermore, NFκB2 mutations
were neither detected in additional cGvHD patients nor in
healthy controls. The TLR2 W558L mutation was found in both
cGvHD patients (21/134, 15.7%) and healthy controls (5/54,
9.3%), but the VAF indicated a 10-fold and 4-fold higher muta-
tion frequency in cGvHD patients’ CD4+ and CD8+ T cells
compared to healthy controls (mean 10.5% vs. 1.3% in CD4+
T cells and mean 8.4% vs. 2.8% in CD8+ T cells, Supplementary
Fig. 3; Supplementary Tables 3, 4).
Functional validation of the somatic mTOR mutation in vitro.
To examine the functional consequences of mTOR P2229R
mutant, we transfected HEK293 cells with mTOR WT and mTOR
P2229R mutant constructs. In standard cell culture conditions,
cell proliferation was significantly increased in HEK293 expres-
sing mTOR P2229R compared to HEK293 expressing mTOR WT
or empty vector (Fig. 3a, b). Since the kinase activity of mTOR is
tightly regulated by nutrient availability, and nutrient starvation
leads to downregulation of mTORC1 signaling and induced
autophagy17, we hypothesized that the mTOR mutation confers
resistance to nutrient starvation-induced cell death. Indeed,
HEK293 cells expressing mTOR P2229R showed increased cell
viability (Fig. 3a, b) together with lower rate of apoptosis (Fig. 3c)
upon serum starvation compared to mTOR WT expressing
HEK293 cells.
As the mTOR signaling pathway consists of two functionally
distinct multi-protein complexes, mTOR complex 1 (mTORC1)
and mTOR complex 2 (mTORC2)18, we next investigated
whether the mTOR P2229R mutant impacts the activation of
these complexes and their downstream targets in the HEK293 cell
line model. While equal overexpression of wild-type and mutant
mTOR was confirmed, no differences in downstream signaling of
either complexes were observed in standard culture conditions
(Supplementary Fig. 4). In contrast, after 12 h of serum
starvation, overexpression of mTOR P2229R mutant was
associated with activation of both mTORC1 and mTORC2
pathways, as evidenced by increased phosphorylation of
mTORC1 targets eukaryotic translation initiation factor 4E
(eIF4E)-binding protein 1 (4E-BP1), ribosomal S6 kinase
(S6K1) and its downstream target ribosomal protein S6, as well
as mTORC2 target AKT (Fig. 3d and Supplementary Fig. 5). We
also observed increased phosphorylation and decreased total
protein level of Forkhead box protein O1 (FoxO1), a direct target
of AKT that regulates T cell differentiation19. Tuberous sclerosis
complex (TSC) 1 and 2 are negative regulators of mTOR20, and
their levels were slightly decreased in cells expressing the mutant
mTOR compared to wild-type mTOR expressing cells upon serum
starvation. The overexpression of TLR2 (W558L) or NFκB2
(P882Q) mutants did not influence protein levels of mTOR
pathway compared to wild-type proteins, suggesting that the
combined effect of triple mutant proteins compared to triple
wild-type proteins on mTOR pathway were solely due to mutant
mTOR (Fig. 3d and Supplementary Fig. 5).
While mTOR is a component of both mTORC1 and mTORC2,
the binding partners are different. Regulatory protein associated
with mTOR (Raptor) and rapamycin insensitive companion of
mTOR (Rictor) bind mTOR in mTORC1 and mTORC2,
respectively18. No differences in overall protein levels of Raptor
or Rictor was observed in HEK293 cells overexpressing mTOR
P2229R compared to wild-type mTOR (Fig. 3d). Furthermore, no
differences in mTOR bound Raptor or Rictor was observed after
immunoprecipitation between P2229R mutant and wild type
mTOR cells (Fig. 3e). DEP domain-containing mTOR-interacting
protein (DEPTOR) is a naturally occurring inhibitor of mTOR
Fig. 1 Flow cytometry and TCRβ deep sequencing results from the index patient. a Gating strategy in screening experiment using the panel of TCR Vβ
antibodies. First, CD3 lymphocyte were separated into CD4+ and CD8+ populations using monoclonal antibodies (CD8+: Pe-Cy7, CD4+: PerCP). Next, the
samples were stained with Vβ specific antibody cocktails included in IO Test Beta Mark TCR beta Repertoire Kit (Beckman-Coulter Immunotech, USA). The
β variable chain family was determined based on FITC and PE positivity from CD4+ and CD8+ populations according to the manufacturer’s instruction.
Vβ20 clone was detected from total CD4+ T cells (52.9%, middle panel) and total CD8+ T cells (1.74%, right). b Flow cytometry Vβ screening results from
the index patient’s peripheral blood sample. T cell clonality with antibodies which target Vβ region of TCR was analysed of CD4+ T cells. The increased
distribution suggests that the cells have large T cell clone. c Increased Vβ20 bearing clonotype over time in the index patient’s CD4+ T cells. Source data
are provided as a Source data file. d T cell repertoire of FACS-sorted CD4+Vβ20+ and CD8+ T cells analysed with TCRβ deep sequencing (Adaptive
Biotechnologies). The TCRBV30-01 clone was detected in the CD4+Vβ20+ fraction, but not in the CD8+ fraction. eMulticolor flow cytometry was applied
to identify the immune phenotype of HSCT donor and index patient’s memory T cell subtypes. Central memory (CM), naïve, effector memory (EM), and
terminal effector memory (TEMRA) cells. f The relative proportion of granzyme B positive (GrB+) CD4+ T cells and GrB+CD8+ T cells in index patient.
Index patient’s PBMCs were stained with anti-CD45,−CD3, −CD4, and−CD8 (surface markers), and then GrB stained after fixation and permeabilization.
Stained cells were analyzed using FACSVerse.
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that inhibits both mTORC1 and mTORC221. The level of mTOR
bound DEPTOR was decreased in cells expressing mTOR P2229R
(Fig. 3e), consistent with increased mTOR activity. Taken
together, our data in HEK293 cells suggests that the mTOR
mutant identified in the index patient leads to gain of function of
both complexes mTORC1 and mTORC2, conferring increased
proliferation in normal culture conditions and reduced apoptosis
upon serum starvation (Fig. 3f). These observations are in line
with other kinase domain mTORmutations identified in cancer15.
As the transcription factor NFκB2 is a critical regulator of
inflammation and immune function22 and toll-like-receptor 2
(TLR2) is one of the pattern recognition receptors important for
the pathogenesis of many autoimmune diseases and highly
expressed in GvHD patients23, we also wanted to study the
functional effects of these mutations. The NFκB2 P882Q mutation
was located in the c-terminal domain (Fig. 2a), which is known to
play an important role in the ubiquitination and partial
proteolysis from NFκB2 (p100) to NFκB2 (p52)24. In order to
determine the molecular balance between these two states, we
performed western blotting in HEK293 cells which revealed an
increased expression of p52 in cells overexpressing the mutant
NFκB2 compared to wild-type NFκB2 (Supplementary Fig. 6a, b)
indicating a gain-of-function alteration. Similarly, to study the
functional consequences of the TLR2 W558L mutation, we
evaluated alterations in transcriptional regulation by analyzing
mRNA expression levels of a subset of TLR2 downstream
targets by qRT-PCR. This demonstrated significantly increased
expression levels of ELK1 and FOS1 in HEK293 expressing
TLR2 W558L mutant as compared to TLR2 WT (Supplementary
Fig. 6c, d).
Paired scRNA- and TCRαβ sequencing of the CD4+ T cells. In
order to better understand the heterogeneity of the Vβ20 bearing
clonotype and the underlying CD4+ T cell compartment in an
unbiased manner, we performed simultaneous single-cell RNA
and paired TCRαβ sequencing on two time points from 2015 and
2017 for the index patient’s CD4+ T lymphocytes from peripheral
blood. From the paired sequencing we received 14,111 CD4+ T
lymphocytes passing the quality control. To analyze possible
differences between the time points, we pooled the samples
together and found six distinct CD4+ phenotypes with graph-
based clustering. Surprisingly, most of the cells (71.8%) were
characterized by cytotoxicity, and lower frequency of naïve cells
(23.4%) and regulatory T cells (4.4%) were identified (Fig. 4a, b)
concordant with the flow cytometry results (Fig. 1e, f). To address
the highly cytotoxic gene expression profile of CD4+ T cells, we
also analyzed CD4+ T cells from a healthy donor and could not
find similar expression of cytotoxic genes (Fig. 4c, d). The fre-
quency of cells in clusters were stable between the time points
indicating resistance to the ongoing immunosuppressive treat-
ment, and only the abundance of cycling cell population showed
over two-fold-change between the two time points (Supplemen-
tary Fig. 7a). From the TCRαβ-seq we detected TCRαβ, TCRα or
TCRβ in 3577 unique T cell clonotypes. The clonotype matching
to TCRβ sequencing data from Vβ20-sorted population (Fig. 1d)
harboring the mTOR-mutation was also the most expanded
fraction, representing 40.1% of the total CD4+ T cells from two
time points. Almost all of the cells from this clonotype (98.4%)
belonged to the cytotoxic clusters, and most of the cells were
included in the cytotoxic effector cluster (85.8%) (Fig. 4e).
To understand the effect of the mTOR-mutation on the T cells,
we performed differential expression (DE) analysis between the
cytotoxic cells, comparing the cells from clonotype of interest
against the other cytotoxic cells in cytotoxic clusters (effector,
effector/effector memory, and memory). The analysis foundT
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1190 statistically significant DE-genes, of which 601 were
upregulated in the clonotype, including cytotoxic genes (e.g.,
GZMA, GZMB, GNLY, GZMK, NKG7, and PRF1) (Fig. 4f).
Additionally, upregulated eukaryote elongation factors (eEFs),
such as EEF1A1, EEF1B2, and EEF2, supported abnormal growth
and proliferation of the expanded CD4+ T cells. Furthermore, the
expression of DUSP2 and KLRB1 genes was highly specific for the
mutated clone (Fig. 4b). To identify differential pathway
regulation in the clonotype, Gene Set Enrichment Analysis
(GSEA) was performed, resulting in 11 significantly over-
represented and 0 under-represented pathways in the clonotype
(Supplementary Table 5). The upregulated pathways included
MYC target pathways, TNFα signaling via NFκB, IL2-STAT5
signaling and hypoxia, supporting that the Vβ20 bearing
clonotype is clearly distinct from the other cytotoxic cells (Fig. 4g).
Cytotoxic GrB+CD4+ T cells are common in patients with
cGvHD. As we observed cytotoxic gene expression signature in
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TLR2 W558L between LRR (Leucine-rich repeats) domain and transmembrane (TM) domain. b A heterozygous mTOR mutation (G to C, P2229R) was
detected in CD4+ T cells by Sanger sequencing. c Variant allele frequencies (VAFs) of mTOR P2229R, NFκB2 P882Q, and TLR2 W558L mutations in the
index patient’s CD4+ T cells over time as measured with amplicon sequencing. Source data are provided as a Source data file. d VAFs (%) of mTOR P2229R
mutation from the index patient’s skin, liver, and eyes biopsy. e Immunofluorescence staining indicated CD3+CD4+ and CD3+CD8+ T cell infiltration in
the skin. Paraffin embedded skin biopsy from the index patient was sectioned and stained with antibody specific human CD3 (cyan), CD4 (green), and CD8
(red). White arrows indicate infiltrated CD3+CD4+ or CD3+CD8+ T cells. Original imaging magnification: 20×, the figure has been further zoomed to 25×
for visualization. Scale bar: 50 μm.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-16115-w
6 NATURE COMMUNICATIONS |         (2020) 11:2246 | https://doi.org/10.1038/s41467-020-16115-w | www.nature.com/naturecommunications
index patient’s CD4+ T cells, we wanted to confirm this finding
by GrB flow cytometry staining in other cGvHD patients’ CD4+
and CD8+ T cells. Interestingly, the GrB positivity was high both
among cGvHD patients’ CD4+ (median 46.1%) and CD8+ T cells
(median 87.0%) when compared to healthy controls (median
2.0% and median 12.8%, respectively, Supplementary Fig. 8a, b).
We also studied the cytokine production capability of GrB+ cells
and noted that patients’ cells were highly active in secreting Th1-
type cytokines (TNF-α and IFN-γ)(Supplementary Fig. 8c, d).
Index patient’s CD4+GrB+ T cells were among the top cytokine
producers when compared to other cGvHD patients (Supple-
mentary Fig. 8c).
CD4+ T cells are cytotoxic against primary fibroblasts. Real-
time electrical impedance measurements monitoring target cell
killing have been widely applied to study the cellular cytotoxicity
in vitro25,26. To test the functional effects of the mutated CD4+
T cells, we performed co-culture experiments with CD4+ and
CD8+ T cells and primary fibroblasts from the index patient.
Addition of purified CD4+ T cells on the monolayer of primary
fibroblasts resulted in dose-dependent decrease in electrical
impedance, implicating cytotoxicity of the CD4+ T cells (Fig. 5a
and Supplementary Fig. 9), a recently defined phenomenon27. In
contrast, the CD8+ T cells showed no cytotoxic activity against
the fibroblasts, as the impedance curve mirrored the control well
without effector cells (Fig. 5a and Supplementary Fig. 9a). To
confirm whether CD4+ T cell cytotoxicity was specific to the
index patient, we performed the cytotoxicity analysis for three
healthy donors. CD4+ and CD8+ T cells from healthy donors did
not show cytotoxic activity against fibroblasts extracted from the
same healthy individuals (Fig. 5c and Supplementary Fig. 9b–d).
We next investigated whether the cytotoxicity of the index
patient’s CD4+ T cells was mediated through major histocom-
patibility complex (MHC) class I or MHC class II by culturing the
patient fibroblasts with HLA I (HLA-ABC) specific or HLA II
(HLA-DR, DP, and DQ) specific monoclonal antibodies before
the addition of CD4+ T cells. HLA I monoclonal antibody
partially rescued the fibroblast viability whereas no impact was
observed with HLA II specific antibody (Fig. 5d). While the exact
mechanism of this effect remains to be studied in more detail,
these data suggest MHC class I mediated fibroblast killing by
cytotoxic CD4+ T cells in the index patient.
Drug sensitivity and resistance testing in CD4+ T cells. To
determine sensitivity of the mutated cells to targeted therapy, we
performed robust ex vivo drug sensitivity and resistance testing
(DSRT) with 527 drugs in five different concentrations28. Freshly
isolated CD4+ T cells from the index patient, the HSCT donor,
and a healthy control were used. In this screen, the index patient’s
CD4+ T cells were less sensitive to mTOR/PI3K inhibitors as
compared to the HSCT sibling donor’s CD4+ T cells (Fig. 6a, b),
although constitutive PI3K/AKT/mTOR activity generally pre-
dicts rapalog sensitivity. Instead, heat shock protein 90 (HSP90)
inhibitors showed an increased killing effect on the index
patient’s CD4+ T cells as compared to CD4+ T cells from both
the HSCT donor and healthy control (Fig. 6a, c, d). With regard
to other clinically interesting drug classes, both the HSCT donor
and the recipient CD4+ T cells were sensitive to HDAC inhibi-
tors, CDK-inhibitors, tyrosine kinase inhibitor, and proteosome
inhibitors. The CD4+ T cells from HSCT donor were also
modestly more sensitive to glucocorticoids (dexamethasone and
methylprednisone), but this was not statistically significant.
Neither HSCT donor nor recipient CD4+ T cells were sensitive to
cyclophosphamide, tacrolimus, or methotrexate. However, it
should be considered that the assay read-out is cell death, andT
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lymphocytes were not activated nor actively proliferating during
the experiment. To elaborate these results, we investigated whe-
ther mTOR or HSP90 inhibitors reduced the cytotoxicity of CD4
+ T cells. For this purpose, we performed the real-time cyto-
toxicity assay with the index patient’s fibroblasts and CD4+
T cells, with drugs added simultaneously with CD4+ T cells to
reduce direct effects on fibroblasts. Both ganetespib (100 nM) and
sirolimus (100 nM) attenuated CD4+ T cell cytotoxicity (Fig. 6e
and supplementary Fig. 10). In line with DSRT result (Fig. 6a–d),
the inhibition of fibroblast killing was slightly higher with gane-
tespib compared to sirolimus.
Next, we studied the effects of these candidate drugs on
mTOR pathway in HEK293 cells. In cells stably expressing
mTOR WT and mTOR P2229R mutant, ganetespib (HSP90
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inhibitor) reduced AKT phosphorylation on serine 473. AKT
phosphorylation appeared to be normal following sirolimus
treatment as rapalogs only inhibit mTORC1, but not mTORC229
activity. Treatment with either drug resulted in decreased levels of
phosphorylated S6K1 in both mutant and WT cells (Fig. 6f). Both
drugs also led to a reduced pS6 phosphorylation in CD4+ T cells
from the index patient and a healthy control (Fig. 6g), suggesting
an inhibitory effect on mTORC1 activity. AKT was more
phosphorylated in the patient’s CD4+ T cells as compared to
controls with a slight decrease in both samples upon treatment
with ganetespib or sirolimus.
Discussion
Chronic GvHD remains a major clinical challenge after allo-
HSCT. Detailed characterization of the immune system using
new analysis tools can give insights into the pathophysiology of
the disease. Peripheral expansion of cytotoxic T cells from the
donor graft is a previously described phenomenon30; however,
whether this clonal expansion is associated with genetic evolution
has not been comprehensively studied.
Here we coupled next-generation DNA sequencing, single-cell
RNA sequencing and TCR sequencing to carefully characterize
the immune phenotype of an index patient with cGvHD. We
identified three somatic candidate mutations in clonally expanded
CD4+ T cells: mTOR, TLR2, and NFκB2. The mTOR mutation
was recurrent and found in total in 2.2% of cGvHD patients. In
the index patient, the mutated clone expanded during the course
of active cGvHD despite immunosuppressive treatment and was
present in both blood and sclerodermatous skin lesion samples
suggesting its contribution to disease pathogenesis. No mutations
were discovered in the sibling donor samples proposing the
mutations been formed after the allo-HSCT. Functional in vitro
studies indicate that the mTOR mutation results in a gain-of-
function alteration activating both mTORC1 and mTORC2
pathways.
Accumulation of somatic mutations is inherently associated
with normal cell division. The role of somatic mutations in cancer
is well established, and recent reports suggest that somatic
mutations may also play a role in the pathogenesis of non-
malignant diseases31–35. It was also recently shown that the dis-
ruption of the TET2 gene by lentiviral vector-mediated insertion
of the chimeric antigen receptor (CAR) transgene led to the
expansion of single CAR T cell in a patient with chronic lym-
phocyte leukemia and enhanced therapeutic efficacy36.
Given the role of mTOR in T cell homeostasis and integrating
immune signals and metabolic clues37, we further characterized
the novel mTOR P2229R mutation in detail. The P2229R
mutation was located in the kinase domain where cancer-
associated gain-of-function mutations have been shown to lead to
activation of both mTORC1 and mTORC2 pathways15,38,39.
Consistent with these prior reports, overexpression of mTOR
P2229R in HEK293 cells resulted in increased cell proliferation
and cell survival compared to wild type mTOR. The mutant
protein effectively activated both mTORC1 and mTORC2
downstream signaling pathways in HEK293 cells upon serum
starvation whereas no differences in the amount of mTOR bound
Raptor or Rictor were observed, suggesting that the mutation did
not influence complex formation. In contrast, the amount of
mTOR bound Deptor, a naturally occurring mTOR inhibitor, was
decreased in mTOR P2229R mutant cells, consistent with gain-of-
function nature of the mutation15.
The other two genes mutated in clonal T cells of the index
patient are also implicated in inflammation40,41. The index
patient harbored NFκB2 (p100) P882Q somatic mutation that is
located in the C-terminus, and our HEK293 model with over-
expression of the mutant NFκB2 suggested increased p52 for-
mation, potentially inducing hyperactivation of non-canonical
NF-κB pathway. Unlike the discovered mTOR and NFκB2
mutations, the TLR2 W558L somatic mutation was identified in
both cGvHD patients and healthy controls; however, VAFs were
significantly higher in cGvHD patients as in healthy controls
(Supplementary Tables 3, 4). While further studies are warranted
to elucidate the relevance of these mutations in cGvHD patho-
genesis, their discovery highlights clonal evolution in the
expanded T cell clone.
Paired scRNA-seq and TCRαβ-seq of the index patient’s blood
samples showed that the majority of the expanded CD4+ T cells
had upregulated expression of genes associated with cytotoxicity
and cellular proliferation. This was further supported by the
ex vivo cytotoxicity assay where the index patient’s mutated CD4
+ T cells, but not CD8+ T cells, possessed dose-dependent
cytotoxicity against the patient’s own primary fibroblasts. Further
experimentation showed partial rescuing of the cytotoxic phe-
notype when fibroblasts where cultured with MHC class I, but not
class II, antibodies before T cells were added. Flow cytometry
staining confirmed that GrB+ CD4+ putative cytotoxic T cells are
common in patients with cGvHD. While the exact mechanism of
this phenomenon is unclear, these data suggest a role for recently
discovered cytotoxic CD4+ T cells42 in GvHD pathogenesis.
The index patient continued to suffer from cGvHD manifes-
tations despite multiple lines of immunosuppressive therapy,
including mycophenolate, prednisone, and cyclosporine. Using
primary patient CD4+ T cells, we performed a large-scale drug
sensitivity screen to identify potential targeted therapies.
Fig. 3 Functional analysis of mTOR, TLR2, and NFκB2 mutants in HEK293 cells. a HEK293 cells stably expressing empty vector (Mock), mTOR WT, and
P2229R (1 × 104 cells) were incubated with or without serum for indicated times. Cell proliferation was measured by DNA fluorescence-based assay. Cell
numbers were calculated with a standard curve from the measured fluorescence intensity. Error bar present mean ± SD of three independent experiments.
p values were calculated using unpaired t-test (mTORP2229R vs. mTORWT). Source data are provided as a Source data file. b Cell morphology after 72 h. c
FACS analysis by Annevin V-FICT/PI double staining of HEK293 cells (Mock, mTORWT, and mTORP2229R) following serum-starvation for 72 h by BD
Accuri™ C6 Plus. Early (Annexin V+/PI−) and late apoptosis (Annexin V+/PI+) are indicated as percentages. d Stably expressed mTORWT, mTORP2229R,
TLR2WT, TLR2W559L, NFκB2WT, NFκB2P882Q, TripleWT (mTORWT, TLR2WT, and NFΚB2WT), and TripleMUT (mTORP2229R, TLR2W559L, and NFΚB2P882Q) in
HEK293 cells were serum starved for 12 h. The cell lysates were subjected to western blot analysis using the indicated antibodies. Data is representative of
three independent experiments. Summary bar plots of the experiment are shown in Suppl. Fig. 5. Source data are provided as a Source data file. e Co-
Immunoprecipitation (Co-IP) of HEK293 stably expressing mTOR WT and P2229R. HEK293 cells stably expressing mTORWT and mTORP2229R are serum
starved for 12 h, and mTOR was immunoprecipitated (IP) with anti-mTOR antibody (1:50 dilution) and immunoblotted (IB) for RAPTOR, PIRCTOR, and
DEPTOR. Respective plots without starvation are shown in Suppl. Fig. 4. Source data are provided as a Source Data file. f Simplified scheme of mTOR
P2229R mutation in the mTOR pathway. Pathway components discovered to be upregulated or downregulated with functional assays are marked with
arrows. Akt protein kinase B, TSC tuberous sclerosis complex, mTOR mammalian target of rapamycin, mTORC1 mTOR complex 1, mTORC2 mTOR
complex 2, Raptor regulatory associated protein of mTOR; rapamycin insensitive companion of mTOR, DEPTOR DEP domain containing mTOR interacting
protein, S6K1 p70 ribosomal S6 kinase 1, S6 S6 ribosomal protein, 4E-BP1 eIF4E-binding protein 1, FoxO1 forkhead family of transcription factor 1.
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Compared to HSCT donor and healthy control, the index
patient’s CD4+ T cells were more sensitive to HSP90 inhibitors.
Consistent with these results, HSP90 inhibitor ganetespib con-
ferred lower killing of primary fibroblasts by CD4+ T cells in the
cytotoxicity assay. HSP90 inhibition has shown efficacy in a
mouse model of GvHD43, and although our results are from a
single patient, our data support the role for HSP90 inhibition in
treating cGvHD. Of note, we also observed resistance of patient
CD4+ T cells to mTOR/PI3K inhibitors compared to donor cells,
consistent with hyperactivation of mTOR pathway due to the
P2229R mutation.
While somatic mutations in clonally expanded T cells in
transplant recipients suffering from cGvHD is an interesting
observation, the generalizability of this phenomenon in cGvHD
remains to be established by further studies.mTOR was mutated in
2.2% (3 out of 135) of cGvHD patients, indicating recurrence of
Fig. 4 Single-cell RNAseq analysis from the index patient. a Two-dimension UMAP-projection of clustered CD4+ cells pooled from two time points from
peripheral blood. A total of 14,111 cells are annotated in six distinct clusters, three of which can be annotated as cytotoxic based on expression of genes
such as GZMA, GZMB, and GNLY. The read counts of scRNA seq data are provided as source file. b Gene expression heatmap for the six distinct CD4+
clusters, where rows represent canonical marker genes and columns represent different clusters. c Feature plot showing the scaled expression of cytotoxic
marker genes across 14,111 CD4+ T cells from the index cGvHD patient in the UMAP embedding. d Feature plot showing the scaled expression of cytotoxic
marker genes across 2322 CD4+ T cells from a healthy donor in the UMAP embedding. e Graphical visualization showing the cells taken into differential
expression analysis. Red shows the Vβ20 bearing, mTORmutated clonotype, and gray cells represent the cells from other clonotypes with similar, cytotoxic
phenotype as the cells from the mutated clonotype. f Volcano plot showing differentially expressed genes between clonotype of interest (red) and cells
from other clonotypes with similar, cytotoxic phenotype as the cells from the mutated clonotype (gray). g Gene Set Enrichment Analysis (GSEA) results
from the differential expression analysis. Shown here are three of six HALLMARK-categories enriched (FDR q-val < 0.05) Vβ20 bearing, mTOR mutated
clonotype.
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Fig. 5 Real-time monitoring of cellular cytotoxicity by electrical impedance measurement. Real-time cell analysing (RTCA) systems, xCELLigenceTM,
was applied to monitor real-time killing effect of primary fibroblasts obtained from the index patient and healthy donors. a Index patient’s primary
fibroblasts were cultured as monolayers for 24 h to reach full confluence. Once confluent, the effector cells; NK-92 cell (positive control, 8:1), primary CD4
+ T cells (4, 8, 16:1) and primary CD8+ T cells (16:1) with different ratios (effector cells:fibroblasts) were added to each well followed by co-culture (arrow
indicates the point of adding the effector cells, 0 h). The control (black line, media) shows the impedance of the fibroblasts without any added effectors.
The cell impedance was measured every 30min for 21 h. The measured impedance was expressed as Cell Index with the normalization performed at time
of addition of effector cells. b Visualization of monolayers of the primary fibroblast before and 21 h after addition of effector cells (8:1 for all effector cells). c
CD4+ T cells and CD8+ T cells from healthy donors were added to healthy donors’ own fibroblasts (n= 3). The cell impedance was measured for 21 h.
Data is representative of three independent individuals. d Index patient’s fibroblasts were seeded with HLA1 and HLA2 antibodies (10 and 20 μg/mL). After
CD4+ T cells (CD4+ T cells:fibroblasts= 8:1) were added the cell impedance was measured for 21 h. Dots represent mean values and error bars indicate
range (n= 2 for all conditions, technical duplicates). Source data are provided as a Source data file.
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these mutations. Furthermore, these mTOR mutations were
detected during active cGvHD emphasizing their role in the
pathogenesis. Whether somatic mutations in cytotoxic T cells are
associated with cGvHD severity, drug responses, and clinical out-
come will have to be validated in larger cGvHD cohorts. Sequential
samples starting from graft are also needed to understand the time
of mutation formation and clonal evolution in detail.
In conclusion, mTOR, NFκB2, and TLR2 somatic mutations
were discovered in an expanded CD4+ T cell clone in a patient
with active cGvHD. mTOR mutation was confirmed to be
recurrent is a small subset of other cGvHD patients, whereas it
was not observed in healthy donors or allo-HSCT patients
without cGvHD. Clonal somatic mutations may also exist in
other genes and cell subsets, warranting further studies to eluci-
date the extend of this phenomenon in the setting of alloimmu-
nity. Our findings imply somatic mutations as one putative
mechanism for the aberrant, persistent T cell activation in
cGvHD and pave the way for potential individualized therapies.
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Methods
Study patients. Index patient’s clinical characteristics and medical history are
described in detail in Supplementary results and Supplementary Fig. 1. The clinical
characteristics of the other two mTOR mutated patients are also described in detail
in Supplementary results. Blood samples from 135 patients who had developed
cGvHD after allo-HSCT were collected between 2007 and 2016 (Helsinki Uni-
versity Hospital, Helsinki, Finland, n= 8; Turku University Hospital, Turku,
Finland, n= 37; Hospital de la Princesa, Madrid, Spain, n= 19; Hospital Morales
Meseguer, Murcia, Spain, n= 71). In addition, 38 patients who had not developed
cGvHD after allo-HSCT until the date of sampling, served as a control cohort
(Turku University Hospital n= 6 and Hospital Morales Meseguer n= 32). The
blood samples were collected 3–102 months (mean 13.5 months) and 2–47 months
(mean 14.5 months) after allo-HSCT for GvHD and non-cGvHD patients,
respectively. Clinical characteristics of the patients are summarized in Supple-
mentary Table 6. All patients provided written informed consents. Additionally,
buffy coat samples from 54 healthy blood donors were obtained from the Finnish
Red Cross Blood Service. A peripheral blood sample from the index patient’s
sibling donor (HSCT donor) was also obtained.
The study was performed in compliance with the principles of Helsinki
declaration, and was approved by the ethics committees in the Helsinki
University Hospital (Helsinki, Finland), Turku University Hospital (Turku,
Finland), Hospital de la Princesa (Madrid, Spain), and Hospital Morales
Meseguer (Murcia, Spain).
Antibodies. Primary antibodies against NFκB2 (Cat#: 4882S, Lot: 4), ribosomal
protein S6 (Clone: 54D2, Cat#: 2317S, Lot#: 4), phospho-S6 ribosomal protein
(Ser235/236) (Clone: D57.2.2E, Cat#: 4858T, Lot#: 16), Akt (Clone: C67E7, Cat#:
4691T, Lot#: 20), phospho-Akt (Ser473) (Cat#: 9271T, Lot#: 14), p70S6 kinase
(S6K) (Clone: 49D7, Cat#: 2708T, Lot#: 7), phospho-p70S6 (S6K) kinase (Thr421/
Ser424) (Cat#: 9204S, Lot#: 11), mTOR (Clone: 7C10, Cat#: 2983, Lot#: 16), p-4E-
BP1 (Clone: 236B4, Cat#: 2855, Lot#: 26), 4E-BP1 (Cat#: 9452, Lot#: 12), Rictor
(Clone: 53A2, Cat#: 2114, Lot#: 7), Raptor (Clone: 24C12, Cat#: 2280, Lot#: 13),
phospho-FoxO1 (Thr24)/FoxO3a (Thr32) (Cat#: 9464, Lot#: 7), FoxO1 (Clone:
C29H4, Cat#: 2880, Lot#: 11), FoxO3a (Clone: 75D8, Cat#: 2497, Lot#: 8), TSC1
(Clone: D43E2, Cat#: 6935, Lot#: 3), TSC2 (Clone: D93F12, Cat#: 4308, Lot#: 6),
and Rabbit IgG Isotype control (Clone: DA1E, Cat#: 3900, Lot#: 34) were pur-
chased from Cell Signaling Technology, and beta-actin (Clone: AC15, Cat#:
ab6276, Lot#: GR66278-11) and HRP‐conjugated VeriBlot for IP secondary anti-
body (Cat#: ab131366, Lot#: GR3295852-1) were purchased from Abcam. IRDye
680 conjugated anti-mouse (Cat#: P/N 926-68070) and IRDye 800 conjugated anti-
rabbit (Cat#: P/N 926-32211) were obtained from LI-COR Biosciences. Deptor
antibody (Cat#: NBP1-49674SS, Lot#: D2) was obtained from Novus Biologicals.
Purified anti human HLA-ABC (Clone: EMR8-5, Cat#: 565292, Lot#: 9080800) and
HLA-DR, DP, DQ (Clone: Mouse IgG2a,κ, Cat#: 555557, Lot#: 9100932) were
purchased from BD Biosciences.
Cell lines. Human embryonic kidney HEK293 (Cat#: CRL-1573, ATCC) and
HEK293FT (Cat#: R70007, Thermo Fisher Scientific) were maintained in high-
glucose Dulbecco Modified Eagle medium (Lonza) containing 10% FBS (Gibco),
1% penicillin-streptomycin (Invitrogen), and L-glutamine (Lonza) in a 37 °C
humidified incubator with 5% CO2. The authentication for HEK293 and
HEK293FT were performed with GenePrint10 System (Promega). The result was
compared to ATCC STR, JCRB STR, ICLC STR database, and DSMZ online STR
database. The identity estimates are calculated according to the allele information
found in these databases. Mycoplasma test was performed using MycoAlert
Mycoplasma Detection Kit (LONZA, Cat#: LT07-318).
Sample preparation and DNA extraction. Mononuclear cells (MNCs) were
separated from whole blood using Ficoll-PaqueTM PLUS (GE Healthcare). The
separated MNCs were then labeled with either CD4+ or CD8+ magnetic beads
(Miltenyi Biotec) and sorted by AutoMACs® cell sorter (Miltenyi Biotec) according
to the manufacturer’s protocol. The purity of sorted fractions was evaluated by flow
cytometry and confirmed to be >98% (FACSVerse, BD Biosciences). Alternatively,
separated MNCs were sorted using FACSAria II (BD Biosciences). Genomic DNA
was isolated from fresh or frozen sorted MNCs or from whole blood samples using
the Genomic DNA NucleoSpin Tissue kit (Macherey-Nagel). DNA concentration
and purity were measured with Qubit2.0 Fluorometer (Invitrogen) or Nanodrop
(Thermo Fisher Scientific).
Flow cytometry analysis and flow-assisted cell sorting. For phenotyping of the
memory T cell subsets, peripheral blood mononuclear cells (PBMCs) were
immunostained with the antibody panel including anti-CD3 PeCy7 (Clone: SK7,
Cat#: 557851, Lot#: 8037645, BD Biosciences), anti-CD4 PerCP (Clone: SK3, Cat#:
345770, Lot#: 6281605, BD Biosciences), anti-CD8 PerCP (Clone: SK1, Cat#:
345774, Lot#: 82152, BD Biosciences), anti-CD45RA Alexa700 (Clone: HI100,
Cat#: 560673, Lot#: 7180940, BD Biosciences), and anti-CCR7 PE (Clone: 150503,
Cat#: FAB197P, Lot#: LEU1618031, R&D System). Stained samples were analyzed
with FACSVerse (BD Biosciences) and FlowJo software (Version 10.4.2). For CD4+
T cell TCR Vβ20+ bearing clonotype sorting, PBMCs were immunostained with
anti-CD3 APC (Clone: SK7, Cat#: 345767, Lot#: 7236657, BD Biosciences), anti-
CD4 PerCP (Clone: SK3, Cat#: 345770, Lot#: 6281605, BD Biosciences), anti-CD8
PE-Cy7 (Clone: SK1, Cat#: 335822, Lot#: 8272690, BD Biosciences) and Vβ20
(IOTest® Beta Mark TCR Vbeta Repertoire Kit, Cat#: IM3497, Lot#: 66, Beckman
Coulter). Stained cells were physically isolated by FACS AriaIII (BD Biosciences).
Purity of sorted cells was more than 99% and verified with the same system.
(Supplementary Fig. 2b). For the analysis of Granzyme B+ T cells, PBMCs were
stained with anti-CD3 APC (Clone: SK7, Cat#: 345767, Lot#: 7236657), anti-CD45
APCH7 (Clone: 2D1, Cat#: 641417, Lot#: 6265575, BD), anti-CD4 PerCP (Clone:
SK3, Cat#: 345770, Lot#: 6281605, BD), and anti-CD8 FITC (Clone: SK1, Cat#:
345772, Lot#: 7235793, BD). Next, cells were fixed and permeabilized using Fix/
Perm (Cat#: 554714, Lot#:7346888, BD) and stained using anti-Granzyme B BV510
(Clone: GB11, Cat#: 563388, Lot#: 9093962, BD), anti-TNF-α V450 (Clone:
MAb11, Cat#: 561311, Lot#: 8127814, BD) and anti-IFN-γ V450 (Clone: B27, Cat#:
560371, Lot#: 5275825, BD). To stimulate T cells, PBMCs were cultured in
RPMI1640 (10% FBS, 1% penicillin/streptomycin, and 2 mM L-glutamin). Stimu-
lation was performed using anti-CD3 APC (Clone: UCHT1, Cat#: 561810, Lot#:
8316946, BD), anti-CD28 (Clone: L293, Cat#: 340975, Lot#: 8277956, BD), anti-
CD49 (Clone: L25, Cat#: 340976, Lot#: 5342638, BD). Protein transport inhibitor,
GolgiSTOPTM containing monensin (Cat#: 554724, Lot#: 9011506, BD), was added
followed by incubation for 16 h at 37 °C.
Immunopanel sequencing. A customized NGS panel including exonic areas of 986
genes related to immunity and cancer was used to screen for somatic mutations12.
Genes included in the panel are provided in the Supplementary Table 7. DNA
library were prepared from NEBNext (New England BioLabs, Cat#: E6040L) and
ThruPLEX DNA-seq (Rubicon Genomics, Cat#: R400407) according to the man-
ufacturers’ instruction. Minor modifications were applied to NEBNext kit: (1) For
ligation 1 μL of 25 μM adapter was used with Illumina Index PE adapter oligo mix.
Primers were purchased from Sigma Aldrich (5′-GATCGGAAGAGCACACGT
CT-3′ and 5′-ACACTCTTTCCCTACACGACGCTCTTCCGATCT-3′). (2) Library
purification was proceeded using Agencourt AMPure XP-beads (Beckman Coulter,
Cat#: A63881). Preparation of pre-capture PCR was performed with 12 cycles of
amplification (15 ng of the ligated library, 5 parallel reactions, initialization: 2 min,
denaturation: 20 s). (3) For forward primer we used Illumina PCR Primer InPE 1.0
(5′-AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGC
Fig. 6 Drug Sensitivity and Resistance testing (DSRT) of CD4+ T cells from index patient compared with CD4+ T cells from both healthy control and
HSCT donor. Ex vivo DSRT was performed on fresh CD4+ T cells from index patient, HSCT donor, and healthy control. Correlation of drug sensitivity
scores (DSS) indicating cell viability inhibition measured by CellTiter-Glo 2.0 (Promega, USA). DSS is a quantitative measurement of a drug response
based on the area under the curve (AUC) with further normalization. Higher DSS denote better killing activity. a Correlation of DSS scores between index
patient and HSCT donor CD4+ T cells. b Individual dose response curves of index patient, HSCT donor, and healthy control CD4+ T cells for mTOR
inhibitors. c Correlation of DSS scores between index patient and healthy control CD4+ T cells. d Individual dose response curves of index patient, HSCT
donor, and healthy control CD4+ T cells for HSP90 inhibitors. e Ganetespib (100 nM) and sirolimus (100 nM) were added with CD4+ T cells after 24 h
when the index patient’s fibroblasts reached full confluence. The cell impedance was measured for 24 h. Dots represent mean values and error bars
indicate range (n= 2 for all conditions, technical duplicates). CD4+ T cells:fibroblasts = 8:1. f Stably expressed mTORWT, mTORP2229R, TripleWT (mTORWT,
TLR2WT, and NFΚB2WT) and TripleMUT (mTORP2229R, TLR2W559L, and NFΚB2P882Q) in HEK293 cells were treated with HSP90 inhibitor (Ganetespib, 100 nM)
or mTOR inhibitor (Sirolimus, 100 nM) for 12 h. Western blot was performed with the use of anti-pAkt, anti-pS6K1, and anti-β-actin antibodies. Different
amount of total protein was loaded in the upper panel (S, 30 μg) and the lower panel (L, 50 μg). Data is representative of three independent experiments.
g Isolated CD4+ T cells from healthy control (HC) and index patient (PT) were treated with HSP90 inhibitor (Ganetespib, 100 nM) or mTOR inhibitor
(Sirolimus, 100 nM) for 12 h. Cells were lysed and proteins were run on the SDS-PAGE gel. Western blot was performed with the use of anti-S6, anti-pS6,
anti-Akt, anti-pAkt, and anti-β-actin antibodies. Source data are provided as a Source data file.
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TCTTCCGATCT-3). Custom made-indexed long reverse primer was merged from
the Illumina PCR Primer InPE 2.0 (5′-GTGACTGGAGTTCA-
GACGTGTGCTCTTCCGATCT-3′) and Illumina TruSeq Small RNA index pri-
mer (5′-CAAGCAGAAGACGGCATACGAGATNNNNNNGTGACTGGAGT
TC-3′, NNNNNN being the selected small RNA index). NNNNNN sequence from
the merged long reverse primer template (5′-CAAGCAGAAGACGGCATACGAG
ATNNNNNN GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT-3′) was
replaced with selected index. For these long reverse primers, the amplification cycle
was modified from 19 cycles to 12 cycles. (4) LM-PCR step in the NimbleGen
protocol was excluded due to sufficient amount of library. Library quantification
was proceeded using Bioanalyzer High sensitivity kit (Agilent, Cat#: 5067-4626).
Target region capture was performed according to NimbleGen SeqCap EZ
Exome Library SR User’s Guide. Minor modifications were applied to NimbleGen
capatures: (1) 10 μL of Illumina PCR Primer InPE 1.0, MPLEX_blockAdapter 2.0
(100 μM, 5′-GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT-3′) and
MPLEX_blockTail2.0 (100 μM, 5′-CAAGCAGAAGACGGCATACGAGAT-3′)
were used in each library for blocking. (2) Four microliter of the captured library
was used in 5 parallel 50 μL amplification reactions. One microliter of NimbleGen
PE-POST1 and PE-POST2 primers (100 μM) were used in each reaction (12
cycles).
ThruPLEX library preparation was performed according to the manufacturer’s
instruction. Hundred nanogram of gDNA was used to mean fragment size of 300
bps by Episonic Multi-Functional Bioprocessor 1100 (Epigentek Group Inc., NY,
USA). The libraries were processed according to ThruPLEX DNA-seq library
preparation kit (Rubicon Genomics, MI, USA) with 50 ng of fragmented DNA. The
libraries were quantitated with Bioanalyzer 2100 (Agilent Technologies, CA, USA).
The captures were performed according to Rubicon Genomics’ protocol for Exome
Capture of ThruPLEX Libraries with Roche NimbleGen SeqCap EZ Library
(Rubicon Genomics, MI, USA). To perform the capture, Roche Nimblegen custom
capture probes were used after hybridization.
Library purification for the amplified libraries (pre-capture preparation with
NEBNext or ThruPLEX) were performed using Agencourt AMPure XP beads
(Beckman Coulter, Cat#: A63881) followed by sequencing quantification using
Illumina HiSeq 2500. Sequencing was done from both sorted CD4+ and CD8+
T cells. Somatic variant-calling pipeline was used with VarScan 2.3.28,44. The
parameters were set to minimum coverage tumor reads: 6, somatic p value: 1,
normal purity: 1 and minimum variant frequency: 0.05. Somatic mutations were
annotated using SnpEff (version 4.0) and Ensembl database (version 68)45,46.
Alignments for the somatic mutations were confirmed in the integrative Genomics
Viewer (IGV, Broad Institute, MA, USA). Variants present in dbSNP130 data sets
were excluded to filter out misclassified germline variants.
Exome sequencing. CD4+ T cells, CD8+ T cells and NK cells of index patient
were used for exome sequencing. Fifty nanogram of DNA was used with Nextera
Rapid Exome Kit (Illumina, Cat#: FC-140-1083). Somatic variants calling were
performed with the same bioinformatics pipeline as with immunopanel
sequencing.
TCR Vβ analysis. TCR Vβ families were analyzed from peripheral whole-blood
samples by flow cytometry-based antibody staining using IOTest® Beta Mark TCR
Vβ Repertoire Kit (Cat#: IM3497, Lot#: 66, Beckman Coulter). Briefly, CD4+ and
CD8+ T cells in whole blood samples were stained with the panel of TCR Vβ
antibodies recognizing 24 members of TCR β chain, which covers about 70% of the
normal human TCR Vβ repertoire. Stained cells were further analyzed using
FACSVerse (BD Biosciences). The corresponding IMGT gene nomenclature for the
vβ segment in the kit is included in the Supplementary Table 8.
TCR CDR3 deep sequencing. Isolated genomic DNAs was used for TCRβ deep
sequencing. Sequencing and data analysis were conducted by Adaptive Bio-
technologies (WA, USA) with ImmunoSEQ assay (Adaptive Biotechnologies, WA,
USA)47. Briefly, raw sequence reads were demultiplexed and adapter and primer
sequences were removed to exclude primer dimer, germline, and contaminant
sequences. To merge closely related sequences, data filtering and clustering were
performed using the relative frequency ratio between similar clones and a modified
nearest algorithm. V, D, and J gene were annotated in accordance with the IMGT
database [http://www.imgt.org/].
Somatic mTOR mutation validation. A specific primer set was designed using the
Primer-Blast search (National Center for Biotechnology Information: http://blast.
ncbi.nlm.nih.gov/) to validate the somatic mTOR mutation (Supplementary
Table 9). Polymerase chain reaction (PCR) products were purified with the
ExoSAP-IT (Affymetrix) followed by sequencing on DNA sequencer (Applied
Biosystems). Sequences were analyzed using 4Peaks version 1.7.1.
Amplicon sequencing of mTOR, NFκB2, and TLR2. Amplicon sequencing was
performed to validate the mutations found in the immunopanel sequencing with
the primers (Supplementary Table 10). Amplicons were amplified with 2-step PCR
protocol. First PCR was done in a volume of 20 µL containing 10 ng of sample
DNA, 10 µL of 2× Phusion High-Fidelity PCR Master Mix and 0.375 µM of each
locus-specific primer. The reaction mix was brought to a final volume with water.
The second PCR was done in a volume of 20 µL containing 1 µL of the amplified
product from the first PCR, 10 µL of 2× Phusion High-Fidelity PCR Master Mix,
0.375 µM of index primer 1 and 0.375 µM of index primer 2. The reaction mix was
brought to a final volume with water.
DNA Engine Tetrad 2 (Bio-Rad Laboratories) or G-Storm GS4 (Somerton)
thermal cyclers were used to cycle the 1-step PCR samples according to the
program: initial denaturation at 98 °C 30 s, 30 cycles at 98 °C for 10 s, at 67 °C for
30 s, and at 72 °C for 15 s, and the final extension at 72 °C for 10 min. Two-step
amplifications were done with the same thermal cyclers. The second PCR (Index
PCR) was done according to the program: initial denaturation at 98 °C 30 s, 8
cycles at 98 °C for 10 s, at 65 °C for 30 s, and at 72 °C for 20 s, and the final
extension at 72 °C for 5 min. The amplified samples were pooled together and the
pool was purified with Agencourt AMPure XP beads (Beckman Coulter, CA, USA)
twice using 1× volume of beads compared to the sample pool volume. Purification
with 1× bead volume removes most of primer dimers from the sample pool.
Agilent 2100 Bioanalyzer (Agilent Genomics, CA, USA) was used to quantify
amplification performance and yield of the purified sample pools. Sample pools
were sequenced with Illumina HiSeq System using Illumina HiSeq Reagent Kit v4
100 cycles kit/MiSeq System using MiSeq 600 cycles kit (Illumina, San Diego,
CA, USA).
Sequencing reads alignment was performed with Bowtie2, and GATK
IndelRealigner was used for local realignment near indel. The coverage was over
100,000×, and a variant was called if variant base frequency was 0.5% of all reads
covering a given a position. All variants with the base quality frequency ratio (ratio
of number of variant calls/numbers of all bases and quality sum of variant calls/
quality sum of all bases at the position) ≥ 0.9 were considered as true somatic
variants8,12.
scRNA-seq and TCRαβ-seq processing. CD4+ T cells from two time points of
the index patient were enriched using CD4 microbeads (Miltenyi Biotec). Single
cells were partitioned using a Chromium Controller (10× Genomics) and scRNA-
seq and TCRαβ-libraries were prepared using Chromium Single Cell 5′ Library &
Gel Bead Kit (10× Genomics), as per manufacturer’s instructions (CG000086 Rev
D). In brief, 17,000 cells from each sample, suspended in 0.04% BSA in PBS were
loaded on the Chromium Single Cell A Chip. During the run, single-cell barcoded
cDNA is generated in nanodroplet partitions. The droplets are subsequently
reversed, and the remaining steps are performed in bulk. Full length cDNA was
amplified using 14 cycles of PCR (Veriti, Applied Biosystems). TCR cDNA was
further amplified in a hemi-nested PCR reaction using Chromium Single Cell
Human T Cell V(D)J Enrichment Kit (10× Genomics). Finally, the total cDNA and
the TCR-enriched cDNA was subjected to fragmentation, end repair and A-tailing,
adapter ligation, and sample index PCR (14 and 9 cycles, respectively). The gene
expression libraries were sequenced using an Illumina NovaSeq, S1 flowcell with
the following read length configuration: Read1= 26, i7= 8, i5= 0, Read2= 91.
The TCR-enriched libraries were sequenced using an Illumina HiSeq2500 in Rapid
Run mode with the following read length configuration: Read1= 150, i7= 8, i5=
0, Read2= 150. The raw data was processed using Cell Ranger 2.1.1. with GRCh38
as the reference genome.
scRNAseq analysis of GvHD patient. Secondary analysis was performed in R
with Seurat 3.0.248. In quality control (QC), cells with fewer than 200 or more than
4000 genes, more than 15% of the counts from mitochondrially-encoded tran-
scripts or did not have TCRα, TCRβ, or TCRαβ were excluded from the analysis.
The remaining data was log-normalized with scaling factor 10,000. To reduce the
dimensionality of the data, we determined the 1000 most highly variable genes with
the FindVariableFeatures-function with “vst” method. The T cell receptor V(D)J-
genes, mitochondrial genes and ribosomal genes (n= 156) were excluded from the
results. We scaled the data based on all genes and performed PCA on the highly
variable genes and the top principal components (PCs) that had standard deviation
higher than 1.5 were kept (n= 10). Clusters were identified using the graph-based
community identification algorithm from the shared-nearest neighbor graph cal-
culated on the PCs as implemented in the Seurat-package. To prevent over-
clustering, the optimal number of clusters was determined by increasing the
resolution hyperparameter as a function of number of clusters until the first
saturation plateau was achieved (in our case resolution = 0.4). The robustness of
these clusters was assessed by subsampling cells and doing the analysis iteratively
and visually inspecting the results of embedding and differentially expressed genes
between the formed clusters. Differential expression analysis was performed based
on the t-test, as suggested by Robinson et al.49 Clusters were annotated using
canonical cell type markers as well as the differentially expressed genes. Gene Set
Enrichment Analysis (GSEA) (software.broadinstitute.org/gsea/index.jsp) between
the clonotype and other cytotoxic cells was performed on genes that were detected
at least in 0.1% of the cytotoxic cells and had at least log fold-change of 0.01
between the clonotype and other cytotoxic CD4+ T cells. The gene list was ordered
based on the fold-change. Overlap with HALLMARK-category was assessed and
the False Discovery Rate (FDR) calculated while the number of permutations was
1000. Clonotypes were identified based on the available information and both total
nucleotide level TCRα and TCRβ were used if found.
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scRNAseq analysis of healthy donor. To compare our findings of CD4+ T cells
from GvHD patient to healthy donor, we downloaded single-cell and protein-level
data of 5247 peripheral blood mononuclear cells from a healthy donor from the
10× website (https://support.10xgenomics.com/single-cell-gene-expression/
datasets/3.1.0/5k_pbmc_protein_v3). The analysis followed the vignette found on
the Seurat webpage (https://satijalab.org/seurat/v3.1/multimodal_vignette.html).
Cells with less than 200 genes were removed from the analysis. We performed
clustering directly on protein levels with shared-nearest neighbor graph and
clustering resolution parameter 0.2 We identified 11 clusters and proceeded to
focus on the two CD4+ T cell clusters, naïve and memory CD4+ T cells. For these,
we performed dimensionality reduction on RNA-level to visualize the expression of
cytotoxic markers.
TCRαβ analysis. From the TCRαβ-seq we detected TCRαβ, TCRα or TCRβ from
14,111 cells, resulting in 3578 different T cell clonotypes. The Vβ20 bearing clo-
notype that harbor the mTOR-mutation was the most expanded, compromising of
4669 cells (33.10%, TRA: CLVGDIGNQGGKLIF; TRB: CAWSTGQANNSPLHF).
However, we noticed that the second most (TRB: CAWSTGQANNSPLHF, 2038
cells, 14.40%) clonotype had only one chain and as its Vβ, Dβ, and Jβ matched to
the most expanded clonotype, we treated this as error coming from uncomplete
sequencing and pooled the two most expanded clonotypes into one.
Analysis of cellular cytotoxicity. Primary fibroblasts from the index patient and
three healthy donors were cultured. Briefly, skin biopsy from the index patient were
dissected in small pieces (approx. 2 mm × 2mm) and transferred into 6-well plate
in 500 µL of complete growth medium containing 20% FBS. 200–300 µL of growth
medium was added for every 2 days to replace evaporated media. After one week,
we increased the amount of media to 2 mL and changed the media every 3 days.
Once cells were confluent in each well, cells were trypsinized and passaged.
To measure cellular cytotoxicity of CD4+ and CD8+ T cells, the proliferation of
the fibroblast was monitored with xCELLigenceTM real-time cell analyzer (RTCA)
(ACEA Biosciences, CA, USA) according to the manufacture’s instruction.
xCELLigenceTM RTCA biosensor measures cellular adhesion through electrical
impedance, which is converted to Cell Index (arbitrary units). CD4+ T cells and
CD8+ T cells were separated from MNCs with CD4+ or CD8+ magnetic beads
(Miltenyi Biotec) and sorted by AutoMACs® cell sorter (Miltenyi Biotec) according
to the manufacturer’s protocol. Briefly, the E-Plate 16 VIEW (ACEA Biosciences,
CA, USA) was equilibrated with the 100 µL of culture media at room temperature.
Next, 100 µL of the cell suspension (fibroblasts, 8 × 103 cells/well) was transferred
to the plate followed by incubation at room temperature for 30 min to allow the
fibroblasts to settle at the bottom of the wells. The xCELLigenceTM monitored the
cells every 30 min for 200 repetitions. When the cell index was reached a plateau,
CD4+ T cells, CD8+ T cells, and NK92 as a cellular cytotoxicity inducer (6.4 × 104
cells as a ratio of the fibroblast to the inducer is 1:8) were added to the fibroblasts.
The real-time impedance trace for the fibroblasts exposed to CD4+ T cells, CD8+
T cells, and NK92 were monitored for 48 h.
The cell index (CI) was calculated according to the formula from RTCA
software (xCELLigenceTM):50
CI tð Þ ¼ R f n; t
  R f n; t0
 
Zn
;
where ƒn is the frequency that impedance measurement is carried out. R (ƒn,t) is
the measured impedance at frequency ƒn at time point t. R (ƒn,t0) is the measured
impedance at frequency ƒn at time point t0 (usually t0 is the time when the
background is measured). Zn is the corresponding frequency factor of ƒn.
Normalized cell index (NCI) which is normalized from the cell index of
different wells was calculated with the following formula:
NCIwell i tð Þ ¼
CIwell i tð Þ
CIwelli tnormalizationð Þ
andCIwell i tnormalizationð Þ≠0;
NCIwell_i(t) is the normalized cell index of well i at time point t. CIwell_i(t) is the Cell
Index of well i at time point t. CIwell_i(tnormalization) is the Cell Index of well i at the
normalization time tnormalization.
Multiplexed immunohistochemistry (mIHC). Tissue blocks were cut in 3.5 µm
sections. Slides were deparaffinized in xylene and rehydrated in graded ethanol
series and H2O. Heat-induced epitope retrieval (HIER) was carried out in 10 mM
Tris-HCl–1 mM EDTA buffer in +99 °C for 20 min (PT Module, Thermo Fisher
Scientific). Peroxide activity was blocked in 0.9% H2O2 solution for 15 min, and
protein block performed with 10% normal goat serum (TBS-NGS) for 15 min.
Anti-CD3 (Clone: EP449E, Cat#: ab52959, Lot#: GR140731, Abcam) primary
antibody diluted 1:500 in protein blocking solution and secondary anti-rabbit
horseradish peroxidase-conjugated (HRP) antibodies (Immunologic) diluted 1:1 in
washing buffer were applied for 1 h 45 min and 45 min, respectively. Tyramide
signal amplification (TSA) 488 (PerkinElmer) was applied on the slides for 10 min.
Thereafter, HIER, peroxide and protein block were repeated, followed by appli-
cation of anti-CD8 (1:500, Clone: C8/144B, Cat#: BSB 5174, Lot#: 5174JDL05,
BioSB) primary antibody, HRP-conjugated secondary antibody diluted 1:3 with
washing buffer and TSA 555 (PerkinElmer). HIER, peroxide block and protein
block were repeated. Then, the slides were incubated with CD4 primary antibodies
(1:25, Clone: EPR6885, Cat#: ab133616, Lot#: GR218457, Abcam) overnight in +4
°C. Next, AlexaFluor647 fluorochrome-conjugated secondary antibody (Thermo
Fisher Scientific) diluted in 1:150 and Dapi (Roche) counterstain diluted 1:250 in
washing buffer were applied for 45 min. ProLong Gold mountant (Thermo Fisher
Scientific) and a coverslip were applied on the slides. After peroxide block, antibody
incubations and fluorochrome reaction, slides were washed three times with 0.1%
Tween-20 (Thermo Fisher Scientific) diluted in 10 mM Tris-HCL buffered saline
pH 7.4 (TBS). Fluorescent images were acquired with the AxioImager.Z2 (Zeiss)
microscope equipped with a Zeiss Plan-Apochromat 20× objective.
Site-directed mutagenesis. Site-directed mutagenesis was conducted using
GENEART® Site-Directed mutagenesis system according to the manufacturer’s
instruction (Invitrogen) with NFκB2 (GeneCopoeia, Cat. EX-Z4293-Lv154), TLR2
(GeneCopoeia, Cat. EX-Q0161-Lv122), and mTOR (Addgene, Cat. 26603)
expression vector. The primer sequences used for the site-directed mutagenesis are
in the Supplemental Table 11.
Establishing stable cell lines. HEK293 cells were transfected using FuGENE HD
transfection reagent (Promega) with either a wildtype or P2229R mTOR expression
vector (ratio of reagent to DNA is 3:1) following the manufacturer’s instruction.
Neomycin resistant clones were selected after the cells were cultured with G418
(500 µg/mL) for 3 weeks. The lentiviruses were produced by co-transfection of
HEK293FT cells with NFκB2 (wildtype or P882Q mutant) or TLR2 (wildtype or
W558L mutant) lentiviral expression vectors, and psPAX2 lentiviral packaging
plasmid (Addgene) and pCMV-VSV-G envelope plasmid (Addgene) using Lipo-
fectamine® 2000 (Thermo Fisher Scientific). Antibiotic-free DMEM containing
10% FBS was used as a culturing medium and Opti-MEM I Reduced Serum
Medium (Thermo Fisher Scientific) supplemented with 5% FBS and 1 mM Sodium
pyruvate was used as a lentivirus packaging medium. Six hours of post-transfec-
tion, medium was removed and replaced with DMEM. After 48 h, the supernatants
were centrifuged at 300×g for 5 min to remove cell debris and filtered with a 0.45
µm polyethersulfone membrane filter. Ultracentrifugation to concentrate the virus
was performed for 2 h at 12,000×g and 4 °C using Beckman SW28 rotor. Lentivirus
titers were measured by p24 specific enzyme-linked immunosorbent assay.
Establishment of triple mutant stable cell lines. HEK293 cells stably expressing
exogenous mTOR (wildtype or P2229R mutant) were transfected with NFκB2 (wild
type or P882Q mutant) expressing lentiviruses. Infections were performed in the
presence of 8 µg/mL of polybrene under centrifugation (500×g, 37°C) for 2 h.
mTOR-NFκB2 transduced cells (expressing Cyan Fluorescent Protein) were selec-
ted by using FACSAriaIII (BD Biosciences). Cells expressing exogenous mTOR-
NFκB2 (wildtype or mutant) were infected with TLR2 (wildtype or W558L mutant)
expressing lentiviruses as described above and selected using puromycin (3 µg/mL).
Western blot analysis and immunoprecipitations. HEK293 cells were washed
twice with cold PBS followed by serum starvation for 12 h. Cells were then har-
vested and further lysed in ice-cold RIPA buffer with 1× protease and phosphatase
inhibitor cocktail (Thermo Fisher Scientific). To remove cell debris, centrifugation
was carried out for 10 min at 4 °C, 12,000×g. Total protein concentration was
measured with the Qubit protein assay (Thermo Fisher Scientific) and protein
samples were prepared in Laemmli buffer (Bio-Rad Laboratories) to load on SDS-
PAGE gel (Bio-Rad). After running the sample in the SDS-PAGE gel, the proteins
were transferred into a nitrocellulose membrane using Trans-blot Turbo transfer
system (Bio-rad) followed by blocking the membrane with Odyssey blocking buffer
(Cat: 927-40000, LI-COR Biosciences) for 1 h. Primary antibodies (1:1000 dilution)
were incubated overnight at 4 °C in the Odyssey blocking buffer with 0.2% Tween
20, and subsequently secondary antibodies (1:15,000 dilution) in the blocking
buffer with 0.2% Tween 20 were incubated for 1 h at room temperature. The
proteins were visualized using Odyssey Imaging Systems (LI-COR Biosciences).
For co-immunoprecipitation, cells were lysed using PierceTM IP lysis buffer (Cat#:
87788, ThermoFisher). One milligram of total cell lysates were pre-cleared with
PureProteome™ Protein A/G Mix Magnetic Beads (Cat#: LSKMAGAG02, Merck)
for 1 h at 4 °C. Pre-cleared supernatants were incubated with anti-mTOR antibody
for overnight at 4 °C under rotation. Magnetic beads were additionally added to the
immune complexes, and then incubated at room temperature for 15 min under
rotation. The immune complexes were washed three times in PBST, resuspended in
the elution buffer and heated at 70 °C for 10 min. Bands were quantified using
ImageJ and uncropped scan of the blots are in the Source data file.
Quantitative reverse transcription PCR (RT-qPCR). Total RNA was extracted
using the RNeasy Mini kit (Qiagen) followed by cDNA synthesis using QuantiNova
Reverse Transcription kit (Qiagen) according to the manufacturer’s protocol. The
cDNA was applied in SYBR Green RT-PCR master mix (Applied Biosystems) and
oligonucleotide primers (Supplementary Table 12). All RT-qPCR reactions were
performed in 384-microwell plates (Applied Biosystem) using a QuantStudio 6 Flex
Real-Time PCR system (Applied Biosystems). The relative quantitation of gene
expression was analyzed using comparative cycle threshold (ΔΔCT) method, and
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beta actin (ACTB) was used as an endogenous control to normalize gene
expression level.
Cell proliferation assay. Cells were seeded in a 96-well plate (1000 cells/well) in
triplicate. Cell proliferation was determined using CyQUANTTM Cell Proliferation
Assay which is similar to the high-content screening assay in sensitivity following
the manufacturer’s instruction (Cat#: C35011, Invitrogen). Briefly, at indicated
time point, 100 μL of detection reagent combined with nucleic acid stain dye and
background suppressor was added to 100 μL of cells in the plate followed by
incubation for 1 h at 37 °C. Fluorescence was measured using FITC filter. Cell
numbers were calculated based on the standard curve according to the manu-
facturer’s protocol.
Drug sensitivity and resistance testing (DSRT). Ex vivo DSRT was performed
on freshly isolated CD4+ T cells with a total of 527 drugs in five concentrations
covering a 10,000-fold concentration range including conventional chemother-
apeutics and a broad range of targeted oncology compounds51. To dissolve the
drug compounds, 5 µL of medium was dispensed into each well of 384-well plates
including five different concentrations of each drug. Twenty microliter of cell
suspension (CD4+ T cells from healthy control, HSCT donor, and index patient:
2000 cells per well) was transferred to every well using MultiFlo FX dispenser
(BioTek). After incubation (5% CO2 at 37 °C) for 72 h, the cell viability was
evaluated by CellTiter-Glo Assay solution (Promega). The drug sensitivity score
(DSS) was calculated to evaluate quantitative drug profiles based on the measured
dose-response curve52.
Statistical analysis. Unpaired two side t-tests and Mann–Whitney test was per-
formed using GraphPad Prism 8 for Mac OS X (version 8.2.1). Multiple test
correction was assessed with Benjamini-Hochberg method implemented in based R
for Mac OS X (version 3.5.1). p-value < 0.05 was considered as statistically sig-
nificant in all analyses as indicated in the figure legends and methods. Normal-
ization of the cell index from the real-time monitoring of cellular cytotoxicity was
performed using xCELLigence RTCA Software (version 2.1.0, ACEA
Biosciences, Inc.).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Data supporting the findings of this work are available within the paper and
its Supplementary Information files. The source data underlying Figs. 1b, d, 2c, 3a, d, e, 4,
5a, c, d, 6a–g, and Supplementary Figs. 3, 4, 5b, 6b, 9a–d, 10a, b, and 11 are provided as a
Source Data file. The TCRB sequence data that support the findings of this study are
available through the ImmuneAccess platform [https://doi.org/10.21417/DK2020NC]
and also in the Supplementary Data 1 ZIP file. The scRNA-seq from healthy control is
available from [https://support.10xgenomics.com/single-cell-gene-expression/datasets/
3.1.0/5k_pbmc_protein_v3]. The read counts of scRNA-seq data from index patient have
been deposited in the ArrayExpress database at EMBL-EBI (www.ebi.ac.uk/arrayexpress)
under the accession number E-MTAB-8911. Somatic variants both from whole exome
sequencing (index patient) and and amplicon sequencing (GvHD patients and healthy
controls) have been deposited in dbSNP (ss2137544086, ss3983910085, ss3983910086,
ss3983910087, ss3983910088, ss3983910089, ss3983910090, ss3983910091,
ss3983910092, ss3983910093, ss3983910094, ss3983910095, ss3983910096,
ss3983910097, ss3983910098, ss3983910099, ss3983910100, ss3983910101,
ss3983910102, ss3983910103, ss3983910104, ss3983910105, ss3983910106,
ss3983910107, ss3983910108, ss3983910109, ss3983910110 [http://www.ncbi.nlm.nih.
gov/SNP/snp_viewTable.cgi?handle=HRUH_MUSTJOKI].
Code availability
All custom scripts made for scRNA-seq, TCRαβ-seq and healthy data are available at
[https://github.com/janihuuh/gvhd_som_mut].
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